IL321066A - Proccesses for the preparation of an nlrp3 inhibitor - Google Patents
Proccesses for the preparation of an nlrp3 inhibitorInfo
- Publication number
- IL321066A IL321066A IL321066A IL32106625A IL321066A IL 321066 A IL321066 A IL 321066A IL 321066 A IL321066 A IL 321066A IL 32106625 A IL32106625 A IL 32106625A IL 321066 A IL321066 A IL 321066A
- Authority
- IL
- Israel
- Prior art keywords
- proccesses
- preparation
- nlrp3 inhibitor
- nlrp3
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202241074900 | 2022-12-23 | ||
| EP23158222 | 2023-02-23 | ||
| PCT/EP2023/087167 WO2024133610A1 (en) | 2022-12-23 | 2023-12-21 | Proccesses for the preparation of an nlrp3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321066A true IL321066A (en) | 2025-07-01 |
Family
ID=89507435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321066A IL321066A (en) | 2022-12-23 | 2023-12-21 | Proccesses for the preparation of an nlrp3 inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260209178A1 (en) |
| EP (1) | EP4638422A1 (en) |
| JP (1) | JP2026502847A (en) |
| KR (1) | KR20250127071A (en) |
| CN (1) | CN120584100A (en) |
| AU (1) | AU2023413741A1 (en) |
| IL (1) | IL321066A (en) |
| MX (1) | MX2025006623A (en) |
| TW (1) | TW202432131A (en) |
| WO (1) | WO2024133610A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360130C (en) * | 2002-04-18 | 2008-01-09 | 先灵公司 | 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists |
| KR20100125316A (en) * | 2008-03-26 | 2010-11-30 | 다이이찌 산쿄 가부시키가이샤 | Hydroxyquinoxalinecarboxamide derivative |
| CN110914256A (en) * | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | Novel sulfonamide carboxamide compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US12479816B2 (en) * | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| KR20240024842A (en) * | 2021-06-23 | 2024-02-26 | 에프. 호프만-라 로슈 아게 | Manufacturing process of NLRP3 inhibitor |
-
2023
- 2023-12-21 EP EP23836842.7A patent/EP4638422A1/en active Pending
- 2023-12-21 KR KR1020257020639A patent/KR20250127071A/en active Pending
- 2023-12-21 CN CN202380088228.8A patent/CN120584100A/en active Pending
- 2023-12-21 IL IL321066A patent/IL321066A/en unknown
- 2023-12-21 AU AU2023413741A patent/AU2023413741A1/en active Pending
- 2023-12-21 JP JP2025536282A patent/JP2026502847A/en active Pending
- 2023-12-21 WO PCT/EP2023/087167 patent/WO2024133610A1/en not_active Ceased
- 2023-12-21 US US19/142,014 patent/US20260209178A1/en active Pending
- 2023-12-22 TW TW112150247A patent/TW202432131A/en unknown
-
2025
- 2025-06-06 MX MX2025006623A patent/MX2025006623A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250127071A (en) | 2025-08-26 |
| CN120584100A (en) | 2025-09-02 |
| US20260209178A1 (en) | 2026-07-23 |
| WO2024133610A1 (en) | 2024-06-27 |
| EP4638422A1 (en) | 2025-10-29 |
| MX2025006623A (en) | 2025-07-01 |
| AU2023413741A1 (en) | 2025-02-20 |
| TW202432131A (en) | 2024-08-16 |
| JP2026502847A (en) | 2026-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287042A (en) | Nlrp3 inflammasome inhibitors | |
| IL307188A (en) | Nlrp3 inhibitors | |
| IL285493A (en) | Crystalline forms of an rsk inhibitor | |
| IL318258A (en) | Novel nlrp3 inflammasome inhibitors | |
| PT4363406T (en) | Nlrp3 inflammasome inhibitors | |
| IL308071A (en) | Process for the preparation of nlrp3 inhibitors | |
| IL306022A (en) | Inhibitors of nlrp3 inflammasome | |
| IL318533A (en) | Nlrp3 inflammasome inhibitors | |
| IL319011A (en) | Triazinone derivatives as nlrp3 inhibitors | |
| IL319009A (en) | Triazinone derivatives as nlrp3 inhibitors | |
| AU2024255473A1 (en) | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 | |
| EP4293018A4 (en) | Compound serving as nlrp3 inhibitor | |
| GB202307924D0 (en) | Inhibitor compounds | |
| GB202300881D0 (en) | Inhibitor compounds | |
| CA3274804A1 (en) | Proccesses for the preparation of an nlrp3 inhibitor | |
| AU2023413741A1 (en) | Proccesses for the preparation of an nlrp3 inhibitor | |
| PT4337652T (en) | Nlrp3 inhibitors | |
| HK40109676A (en) | Inhibitors of nlrp3 | |
| CA3280638A1 (en) | Inhibitors of nlrp3 | |
| TWI926416B (en) | Inhibitor compounds for selective passivation of surfaces | |
| HK40122649A (en) | Nlrp3 inhibitors | |
| HK40064714A (en) | Crystalline forms of an rsk inhibitor | |
| HK40099180A (en) | Inhibitors of nlrp3 inflammasome | |
| CA3288941A1 (en) | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 | |
| HK40098588A (en) | Polymorphs of an ssao inhibitor |